Stocks Bristol-Myers Squibb Co

More

  • Pfizer earnings fall but tops Street 4Q forecasts Tuesday, 2 Feb 2016 | 6:55 AM ET

    Pfizer Inc.' s fourth-quarter profit fell by half due to higher costs for production, administration and restructuring, but new revenue from an acquisition helped the world's second-biggest drugmaker beat Wall Street expectations. For the first time in five years, Pfizer posted higher revenue, excluding the impact of unfavorable exchange rates, as its 2015...

  • TRENTON, N.J.— Patients with hepatitis C have yet another advanced treatment option, as the Food and Drug Administration on Thursday approved a new once-a-day pill developed by drugmaker Merck. The FDA said Merck can begin marketing Zepatier for patients with two of the subtypes the liver-destroying virus, types 1 and 4. Merck& Co. said the price will be $54,600...

  • U.S. stock index futures indicated a mixed open Thursday after December durable goods orders declined far more than expected.

  • TRENTON, N.J.— Bristol-Myers Squibb Co. swung from a tiny profit to a loss in the fourth quarter as it fought multiple headwinds, but it still beat Wall Street expectations. However, the New York- based company's adjusted fourth-quarter results, which exclude $785 million in after-tax charges for numerous one-time items, came to a profit of $647 million, or 38 cents...

  • Bristol-Myers reports 4Q loss Thursday, 28 Jan 2016 | 7:17 AM ET

    NEW YORK— Bristol-Myers Squibb Co. on Thursday reported a fourth-quarter loss of $138 million, after reporting a profit in the same period a year earlier. The average estimate of 11 analysts surveyed by Zacks Investment Research was for earnings of 28 cents per share. Seven analysts surveyed by Zacks expected $4.09 billion.

  • Trading struggling biotech: 4 stocks to watch Monday, 11 Jan 2016 | 7:17 PM ET
    A Merck sign in front of the company's building in Summit, New Jersey.

    Biotech stocks endured a rough Monday, and struggles may continue throughout the year for the high-growth sector, one trader said.

  • Jan 7- Dynavax Technologies Corp said its experimental hepatitis B vaccine was found to be safe and effective in a late-stage study, paving the way for the company to resubmit its marketing application. The earlier marketing application for the vaccine, HEPLISAV-B, was rejected in February 2013 by the U.S. Food and Drug Administration, which sought additional...

  • Your first trade for 2016 Thursday, 31 Dec 2015 | 6:51 PM ET

    The "Fast Money" traders give their final trades for 2015.

  • NEW YORK, Dec 23- A new class of blood thinners that competes with widely used warfarin should get a boost next year when an "antidote" that can reverse the medications' effects in an emergency is expected to enter the market, according to top U.S. heart doctors and investors. Xarelto, from Bayer AG and Johnson& Johnson, and Eliquis, sold by Bristol-Myers Squibb and...

  • Lightning Round: Your portfolio insurance policy Monday, 21 Dec 2015 | 7:00 PM ET
    Mad Money Lightning Round

    Jim Cramer rattles off his take on caller favorite stocks, including this play on commodities.

  • Stock futures sink as traders brace for wild ride Friday, 18 Dec 2015 | 7:38 AM ET

    U.S. stock futures were lower this morning, ahead of the prospect for greater volatility and volume on the final Friday of the year for quadruple witching.

  • LONDON, Dec 16- Bristol-Myers Squibb's closely watched new drug Opdivo, one of the first of a new wave of cancer medicines that boost the immune system, has been rejected as too expensive for treating lung cancer by Britain's cost watchdog. However, the head of Britain's leading cancer research center said companies needed to do more to bring down the cost of such...

  • LONDON, Dec 16- Bristol-Myers Squibb's closely watched new drug Opdivo, one of the first of a new wave of cancer medicines that boost the immune system, has been rejected as too expensive for treating lung cancer by Britain's cost watchdog. In draft guidance issued on Wednesday, the National Institute for Health and Care Excellence said using Opdivo in non-small...

  • Your first trade for Tuesday Monday, 14 Dec 2015 | 6:25 PM ET

    The "Fast Money" traders give their final trades of the day.

  • FRANKFURT, Dec 9- European and U.S. drug regulators are looking into whether a defective blood clotting test device affected a trial involving Bayer's top-selling anti-clotting drug Xarelto, hitting the German drugmaker's shares. "Due to the defect it is now thought that the INR device may have impacted the clotting results in some patients in the warfarin...

  • BERLIN, Dec 9- European and U.S. drug regulators are looking into whether a defective blood-clotting test device affected a trial involving Bayer's blockbuster anti-blood clotting drug Xarelto, hitting the German drugmaker's shares. Bayer and Duke University's Clinical Research Institute, which conducted some of the trial work and which used the device in...

  • LONDON, Dec 4- The cost of cancer drugs varies substantially across Europe, experts said on Friday in a new analysis that is likely to fuel debate about the rising cost of modern medicines. But there are also wide gaps in Europe, according to Wim van Harten of the Netherlands Cancer Institute and colleagues, writing in the journal Lancet Oncology.

  • Nov 30- The U.S. Food and Drug Administration said on Monday it had approved a drug to be sold by Bristol-Myers Squibb Co as a treatment for a form of blood cancer. The FDA said it approved the treatment, Empliciti, to be used in multiple myeloma patients in combination with Celgene Corp's Revlimid and common anti-inflammatory drug dexamethasone.

  • Nov 27- Bristol-Myers Squibb Co said the U.S. Food and Drug Administration declined to approve its immuno-oncology drug, Opdivo, for its expanded use to treat an additional type of advanced skin cancer. The FDA approved Opdivo as a single agent for the treatment of patients with BRAF V600 wild-type melanoma earlier this week, but on Friday declined the approval...

  • FDA approves Bristol's Opdivo for kidney cancer Monday, 23 Nov 2015 | 3:25 PM ET

    Nov 23- U.S. Food and Drug Administration approved Bristol-Myers Squibb Co's drug, Opdivo, for treatment of advanced renal cell carcinoma, a type of kidney cancer. The drug is already approved to treat advanced melanoma and a common form of lung cancer. Opdivo belongs to a highly promising new class of medicines called PD-1 inhibitors that block a mechanism used...